Results 61 to 70 of about 11,143 (189)
Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome
American Journal of Hematology, Volume 101, Issue 9, Page 2147-2156, September 2026.ABSTRACT Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associated with systemic diseases, particularly lymphoproliferative disorders (LPDs) and myeloproliferative ...
Alessandro Ciavarella +10 more
wiley +1 more source
Percutaneous versus open cannulation for mechanical support in patients with right ventricular failure after left ventricular assist device placement [PDF]
Exploration of CardiologyAim: Temporary right ventricular assist device (t-RVAD) is an option for those patients in right ventricular failure (RVF) after left ventricular assist device (LVAD) resistant to ionotropic therapy.
Amit Prasad +4 more
doaj +1 more source
LVAD Vasculitis Case Series: Suggestion of a New Fatal LVAD-Related Phenomenon.
JACC. Case reports, 2021 Left ventricular assist devices (LVADs) are surgically implanted mechanical devices indicated for patients with advanced heart failure and are known to come with several complications. Here we present a case series, and review 1 documented report, of LVAD vasculitis, a presumed new LVAD immune/humoral related phenomenon. (Level of Difficulty: Advanced.)
Garcia, Raul Angel +9 more
openaire +2 more sources
The Therapeutic Potential of H2S‐Releasing Platforms in Cardiovascular Applications
Journal of Biomedical Materials Research Part B: Applied Biomaterials, Volume 114, Issue 8, August 2026.The Therapeutic Potential of H2S‐Releasing Platforms. ABSTRACT Once known as a toxic gas, hydrogen sulfide (H2S) is now making its way into many therapeutic applications. Similar to its other fellow endogenous gasotransmitters, nitric oxide and carbon monoxide, H2S is a small gas with a short half‐life, making it extremely capable of penetrating ...
Tia N. Shorter, Elizabeth J. Brisbois
wiley +1 more source
Mediators of Inflammation, 2013 Background. Inflammation is a critical process contributing to heart failure (HF). We hypothesized that IL-33/ST2 pathway, a new mechanism regulated during cardiac stress, may be involved in the functional worsening of end-stage HF patients, candidates ...
C. Caselli +11 more
doaj +1 more source
Biomedical Papers, 2016 Aims: One of the proposed limitations of left ventricular assist device (LVAD) therapy is high degree of sensitization. Apart from human leukocyte antigen (HLA), antibodies against Angiotensin II Type 1 Receptor (AT1R) have been associated with adverse ...
Marian Urban +4 more
doaj +1 more source
Artificial Organs, Volume 50, Issue 8, Page 1153-1163, August 2026.Local application of gentamicin for wound closure after full‐support microaxial flow pump therapy. ABSTRACT Background Surgically implanted microaxial flow pumps (mAFP) are increasingly used for cardiogenic shock treatment. Standard mAFP explantation is performed bedside with a shortening of the vascular prosthesis, which may represent a potential ...
Gaik Nersesian +11 more
wiley +1 more source
Artificial Organs, Volume 50, Issue 8, Page 1164-1169, August 2026.Direct intraoperative HeartMate 3 LVAD flow measurements using an ultrasonic probe revealed consistently higher values by approximately 0.5 L/min compared to device‐estimated flows. This discrepancy remained stable across pump speed settings, highlighting the importance of distinguishing measured from estimated flow in HeartMate 3 patients.
Gaik Nersesian +13 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Myocardial fibrosis is prevalent in cardiomyopathies that result in heart failure with reduced ejection fraction. Heart failure with reduced ejection fraction treated with a left ventricular assist device (LVAD) yields hemodynamic unloading ...
Rachel M. Biggs +15 more
doaj +1 more source
Implantable devices: a bridge to heart transplantation
Вестник трансплантологии и искусственных органов, 2019 Terminal stage heart failure represents a substantial worldwide problem for the healthcare system. Despite significant improvements (medical heart failure treatment, implantable cardioverters, cardiac resynchronization devices), long-term survival and ...
D. Zimpfer, D. Wiedemann, A. Neissner
doaj +1 more source